Mirum Pharmaceuticals, Inc. Interest Expense Nonoperating
Mirum Pharmaceuticals, Inc. (MIRM) reported Interest Expense Nonoperating of $2.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $2.62M, a 27.05% decline year-over-year.
- Mirum Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $3.62M, a 0.56% increase year-over-year.
- Mirum Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $3.60M, a 0.53% increase year-over-year.
- Mirum Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $3.61M, a 0.56% increase year-over-year.
- Mirum Pharmaceuticals, Inc. interest expense nonoperating for fiscal 2025 was $14.39M, a 0.55% increase from fiscal 2024.
- Mirum Pharmaceuticals, Inc. interest expense nonoperating for fiscal 2024 was $14.31M, a 5.26% decline from fiscal 2023.
- Mirum Pharmaceuticals, Inc. interest expense nonoperating for fiscal 2023 was $15.11M, a 5.47% decline from fiscal 2022.
- Mirum Pharmaceuticals, Inc. interest expense nonoperating for fiscal 2022 was $15.98M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.62M 10-Q · filed 2026-08-05 | $6.23M 10-Q · filed 2026-08-05 | $9.83M derived: sum of 3 quarters · filed 2026-08-05 | $13.44M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $3.62M 10-Q · filed 2026-05-06 | $7.21M derived: sum of 2 quarters · filed 2026-05-06 | $10.82M derived: sum of 3 quarters · filed 2026-05-06 | $14.41M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $7.20M derived: sum of 2 quarters · filed 2026-02-25 | $10.79M derived: sum of 3 quarters · filed 2026-08-05 | $14.39M 10-K · filed 2026-02-25 |
| 2025-09-30 | $3.61M 10-Q · filed 2025-11-04 | $7.20M derived: sum of 2 quarters · filed 2026-08-05 | $10.79M 10-Q · filed 2025-11-04 | $14.37M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $3.59M 10-Q · filed 2026-08-05 | $7.18M 10-Q · filed 2026-08-05 | $10.76M derived: sum of 3 quarters · filed 2026-08-05 | $14.35M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $3.60M 10-Q · filed 2026-05-06 | $7.17M derived: sum of 2 quarters · filed 2026-05-06 | $10.76M derived: sum of 3 quarters · filed 2026-05-06 | $14.33M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $3.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $7.17M derived: sum of 2 quarters · filed 2026-02-25 | $10.73M derived: sum of 3 quarters · filed 2026-02-25 | $14.31M 10-K · filed 2026-02-25 |
| 2024-09-30 | $3.59M 10-Q · filed 2025-11-04 | $7.16M derived: sum of 2 quarters · filed 2025-11-04 | $10.73M 10-Q · filed 2025-11-04 | $14.29M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $3.57M 10-Q · filed 2025-08-06 | $7.15M 10-Q · filed 2025-08-06 | $10.71M derived: sum of 3 quarters · filed 2026-02-25 | $14.28M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $3.58M 10-Q · filed 2025-05-07 | $7.14M derived: sum of 2 quarters · filed 2026-02-25 | $10.71M derived: sum of 3 quarters · filed 2026-02-25 | $14.44M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $3.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $7.14M derived: sum of 2 quarters · filed 2026-02-25 | $10.86M derived: sum of 3 quarters · filed 2026-02-25 | $15.11M 10-K · filed 2026-02-25 |
| 2023-09-30 | $3.57M 10-Q · filed 2024-11-12 | $7.30M derived: sum of 2 quarters · filed 2024-11-12 | $11.54M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $3.73M 10-Q · filed 2024-08-07 | $7.97M 10-Q · filed 2024-08-07 | ||
| 2022-12-31 | $15.98M 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |